©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 6, 2019; 7(23): 4036-4043
Published online Dec 6, 2019. doi: 10.12998/wjcc.v7.i23.4036
Published online Dec 6, 2019. doi: 10.12998/wjcc.v7.i23.4036
In-vitro proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report
Takashi Anayama, Mai Taguchi, Takehiro Tatenuma, Hironobu Okada, Ryohei Miyazaki, Kentaro Hirohashi, Motohiko Kume, Kazumasa Orihashi, Department of Surgery II, Kochi Medical School, Kochi University, Kochi 783-8505, Japan
Keisuke Matsusaki, Japanese CART Study Group, Kaname Second Clinic, Kanamecho Hospital, Tokyo 171-0043, Japan
Author contributions: Anayama T organized the entire study protocol and mainly wrote the manuscript; Taguchi M and Tatenuma T performed the CD-DST; Okada H and Kume M performed the KM-CART; Miyazaki R, Hirohashi K, and Kume M were responsible for the clinical treatment of the patient; Orihashi K was responsible for the entire study.
Informed consent statement: The patient agreed to all treatments. Every treatment was performed after obtaining written informed consent from the patient.
Conflict-of-interest statement: The authors have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Takashi Anayama, MD, PhD, Associate Professor, Department of Surgery II, Kochi Medical School, Kochi University, 2-5-1akebono-cho, Kochi-shi, Kochi 783-8505, Japan. anayamat@kochi-u.ac.jp
Telephone: +81-88-8802375 Fax: +81-88-8802376
Received: August 13, 2019
Peer-review started: August 13, 2019
First decision: September 23, 2019
Revised: November 8, 2019
Accepted: November 14, 2019
Article in press: November 14, 2019
Published online: December 6, 2019
Processing time: 114 Days and 22 Hours
Peer-review started: August 13, 2019
First decision: September 23, 2019
Revised: November 8, 2019
Accepted: November 14, 2019
Article in press: November 14, 2019
Published online: December 6, 2019
Processing time: 114 Days and 22 Hours
Core Tip
Core tip: Massive ascites due to recurrent malignant mesothelioma was controlled with innovative cell-free and concentrated ascites reinfusion therapy, and the derived tumor cells were utilized secondarily in an in vitro cell growth assay that contributed to the personalized chemotherapy for the patient.